(Q46618426)

23 December 2017

title

Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients (English)

1 reference

23 December 2017

1 reference

3

1 reference

23 December 2017

author name string

Amy E Miller

series ordinal

1

1 reference

23 December 2017

Laura B Hansen

series ordinal

2

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 May 2008

1 reference

23 December 2017

published in

Pharmacotherapy

1 reference

23 December 2017

volume

28

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

553-561

1 reference

23 December 2017

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

A retrospective cohort study of correlates of response to pharmacologic therapy for hyperlipidemia in members of a managed care organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Evaluation of patient and provider satisfaction with a pharmacist-managed lipid clinic in a Veterans Affairs medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Achieving cholesterol target in a managed care organization (ACTION) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Development of a pharmacist-managed lipid clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Quality assessment of dyslipidemia in managed care: current best evidence should be used to benchmark quality

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

Standards of medical care in diabetes--2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.28.5.553

21 January 2018

Identifiers

DOI

10.1592/PHCO.28.5.553

1 reference

23 December 2017

1 reference

23 December 2017